118 related articles for article (PubMed ID: 9365163)
1. Enhancement by O6-benzyl-N2-acetylguanosine of N'-[2-chloroethyl]-N-[2-(methylsulphonyl)ethyl]-N'-nitrosourea therapeutic index on nude mice bearing resistant human melanoma.
Debiton E; Cussac-Buchdhal C; Mounetou E; Rapp M; Dupuy JM; Maurizis JC; Veyre A; Madelmont JC
Br J Cancer; 1997; 76(9):1157-62. PubMed ID: 9365163
[TBL] [Abstract][Full Text] [Related]
2. Enhancement by O6-benzyl-N-acetylguanosine derivatives of chloroethylnitrosourea antitumor action in chloroethylnitrosourea-resistant human malignant melanocytes.
Cussac C; Rapp M; Mounetou E; Madelmont JC; Maurizis JC; Godeneche D; Dupuy JM; Sauzieres J; Baudry JP; Veyre A
J Pharmacol Exp Ther; 1994 Dec; 271(3):1353-8. PubMed ID: 7996446
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-benzyl-N2-acetylguanosine increases chloroethylnitrosourea-induced apoptosis in Mer+ human melanoma cells.
Debiton E; Glasser AL; Marchenay C; Rolhion C; Maurizis JC; Madelmont JC
Melanoma Res; 2002 Oct; 12(5):417-27. PubMed ID: 12394182
[TBL] [Abstract][Full Text] [Related]
4. Disposition and metabolism of O6-alkylguanine-DNA alkyltransferase inhibitor in nude mice bearing human melanoma.
Cussac C; Mounetou E; Rapp M; Madelmont JC; Maurizis JC; Labarre P; Chollet P; Chabard JL; Godeneche D; Baudry JP
Drug Metab Dispos; 1994; 22(4):637-42. PubMed ID: 7956741
[TBL] [Abstract][Full Text] [Related]
5. Melanoma-cell toxicity of cystemustine combined with O6-benzyl-N2-acetylguanosine.
Buchdahl C; Rolhion C; Glasser AL; Debiton E; Mounetou E; Madelmont JC; Laval F
Melanoma Res; 1998 Apr; 8(2):123-30. PubMed ID: 9610864
[TBL] [Abstract][Full Text] [Related]
6. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells.
Godeneche D; Rapp M; Thierry A; Laval F; Madelmont JC; Chollet P; Veyre A
Cancer Res; 1990 Sep; 50(18):5898-903. PubMed ID: 2393861
[TBL] [Abstract][Full Text] [Related]
7. O6-(alkyl/aralkyl)guanosine and 2'-deoxyguanosine derivatives: synthesis and ability to enhance chloroethylnitrosourea antitumor action.
Mounetou E; Debiton E; Buchdahl C; Gardette D; Gramain JC; Maurizis JC; Veyre A; Madelmont JC
J Med Chem; 1997 Aug; 40(18):2902-9. PubMed ID: 9288172
[TBL] [Abstract][Full Text] [Related]
8. A new O6-alkylguanine-DNA alkyltransferase inhibitor associated with a nitrosourea (cystemustine) validates a strategy of melanoma-targeted therapy in murine B16 and human-resistant M4Beu melanoma xenograft models.
Rapp M; Maurizis JC; Papon J; Labarre P; Wu TD; Croisy A; Guerquin-Kern JL; Madelmont JC; Mounetou E
J Pharmacol Exp Ther; 2008 Jul; 326(1):171-7. PubMed ID: 18411412
[TBL] [Abstract][Full Text] [Related]
9. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model.
Demidem A; Morvan D; Papon J; De Latour M; Madelmont JC
Cancer Res; 2001 Mar; 61(5):2294-300. PubMed ID: 11280801
[TBL] [Abstract][Full Text] [Related]
10. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide.
Kokkinakis DM; Bocangel DB; Schold SC; Moschel RC; Pegg AE
Clin Cancer Res; 2001 Feb; 7(2):421-8. PubMed ID: 11234899
[TBL] [Abstract][Full Text] [Related]
11. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation.
Mitchell RB; Moschel RC; Dolan ME
Cancer Res; 1992 Mar; 52(5):1171-5. PubMed ID: 1737376
[TBL] [Abstract][Full Text] [Related]
12. Treatment of human brain tumor xenografts with O6-benzyl-2'-deoxyguanosine and BCNU.
Schold SC; Kokkinakis DM; Rudy JL; Moschel RC; Pegg AE
Cancer Res; 1996 May; 56(9):2076-81. PubMed ID: 8616853
[TBL] [Abstract][Full Text] [Related]
13. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts.
Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL
Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735
[TBL] [Abstract][Full Text] [Related]
14. Cystemustine INSERM.
Palmer B
IDrugs; 1998 May; 1(1):129-35. PubMed ID: 18465517
[TBL] [Abstract][Full Text] [Related]
15. G2 accumulation and melanin overproduction in malignant melanocytes treated with a new nitrosourea.
Buchdahl C; Papon J; Communal Y; Bourges M; Madelmont JC
Melanoma Res; 1998 Dec; 8(6):517-27. PubMed ID: 9918414
[TBL] [Abstract][Full Text] [Related]
16. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of nitrosourea-resistant Mer+ human tumor cells to N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea by mild (41 degrees C) hyperthermia.
Mulcahy RT; Gipp JJ; Tanner MA
Cancer Res; 1988 Mar; 48(5):1086-90. PubMed ID: 3342391
[TBL] [Abstract][Full Text] [Related]
18. Eradication of human medulloblastoma tumor xenografts with a combination of O6-benzyl-2'-deoxyguanosine and 1,3-bis(2-chloroethyl)1-nitrosourea.
Kokkinakis DM; Moschel RC; Pegg AE; Schold SC
Clin Cancer Res; 1999 Nov; 5(11):3676-81. PubMed ID: 10589786
[TBL] [Abstract][Full Text] [Related]
19. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: an evaluation in a human melanoma xenograft model.
Wedge SR; Porteous JK; Newlands ES
Cancer Chemother Pharmacol; 1997; 40(3):266-72. PubMed ID: 9219512
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of BCNU anticancer activity by O6-benzylguanine: a study in vitro and in vivo.
Wan Y; Wu D; Gao H; Lu H
J Environ Pathol Toxicol Oncol; 2000; 19(1-2):69-75. PubMed ID: 10905510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
